Glucose Regulates Insulin Gene Transcription by Hyperacetylation of Histone H4*

Amber L. Mosley and Sabire Özcan {ddagger}

From the Department of Molecular and Cellular Biochemistry, Chandler Medical Center, University of Kentucky, Lexington, Kentucky 40536

Received for publication, December 4, 2002 , and in revised form, March 5, 2003.
    ABSTRACT
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Induction of insulin gene expression in response to high blood glucose levels is essential for maintaining glucose homeostasis. Although several transcription factors including Beta-2, Ribe3b1, and Pdx-1 have been shown to play a role in glucose stimulation of insulin gene expression, the exact molecular mechanism(s) by which this regulation occurs is unknown. Previous data demonstrate that the transcription factors Beta-2/NeuroD1 and Pdx-1, which are involved in glucose-stimulated insulin gene expression, interact with the histone acetylase p300, suggesting a role for histone acetylation in glucose regulation of the insulin gene expression. We report that exposure of mouse insulinoma 6 cells to high concentrations of glucose results in hyperacetylation of histone H4 at the insulin gene promoter, which correlates with the increased level of insulin gene transcription. In addition, we demonstrate that hyperacetylation of histone H4 in response to high concentrations of glucose also occurs at the glucose transporter-2 gene promoter. Using histone deacetylase inhibitors, we show that increases in histone H4 acetylation cause stimulation of insulin gene transcription even in the absence of high concentrations of glucose. Furthermore, we show that fibroblasts, which lack insulin gene expression, also lack histone acetylation at the insulin gene promoter. In summary, our data support the idea that high concentrations of glucose stimulate insulin gene expression by causing hyperacetylation of histone H4 at the insulin gene promoter.


    INTRODUCTION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Type II diabetes is a multifactorial disease caused by a combination of defects in insulin production, insulin secretion, and insulin action. To maintain glucose homeostasis, it is imperative that insulin transcription, translation, and secretion are up-regulated in the {beta} cells of the pancreas in response to high blood glucose levels (1). The pancreatic {beta} cells respond to high blood glucose levels first by secreting insulin from the secretory granules followed by up-regulation of insulin gene transcription and translation as a more long term response (1). A number of other proteins have also been shown to be required for the glucose responsiveness of pancreatic {beta} cells, including glucokinase and glucose transporter-2 (GLUT-2)1 (2, 3). The expression of GLUT-2 has been shown to be up-regulated by glucose in pancreatic {beta} cells (4, 5, 6). The regulation of glucokinase gene expression by glucose remains unclear (7, 8); however, several of the transcription factors required for its expression are also involved in glucose regulation of gene expression (9).

Studies on the regulation of the insulin gene promoter by glucose revealed a number of enhancer elements that contribute to the glucose responsiveness of this promoter (10). This includes the E1/E2 (11), A3/A4 (12, 13), C1 (14, 15), and Za1 (16) enhancer elements. Transcription at the insulin gene promoter is regulated by various complex interactions between different transcription factors to merge signals from a variety of different pathways. The transcription factors that have been shown to be important for glucose-regulated insulin gene expression include the {beta} helix-loop-helix protein E47/Pan1 (11) and Beta-2/NeuroD1 (17), which bind to the E elements. It also includes the {beta} cell-specific homeodomain transcription factor Pdx-1 (18, 19, 20), which binds to the A elements, and Ribe3b1, a recently cloned glucose-regulated factor that encodes a homologue of mammalian MafA proteins that binds to the C1 element of the insulin gene promoter (14, 21, 22, 23). Although it has been shown that these transcription factors are required for glucose-stimulated insulin gene expression (9, 24, 25, 26, 27), the exact mechanism(s) by which they stimulate insulin gene expression in response to high blood glucose levels are unknown.

Transcriptional regulation of eukaryotic genes is a very complex process that requires the cooperation of a number of transcription factors, as well as various co-activator and co-repressor proteins, which modulate histone structure (28, 29). Changes in histone modification have been shown to increase or decrease the accessibility of promoters to the transcription machinery, thereby leading to repression or activation of gene expression (28, 29, 30, 31, 32). A number of modifications have been shown to modulate histone structure including acetylation (33, 34, 35, 36), phosphorylation (37), and methylation (28, 38). In the case of histone acetylation, it has been demonstrated that a cooperation between histone acetylases and deacetylases leads to activation of gene expression only in response to specific stimuli (35, 39).

Previous data indicate that two of the insulin gene transcription factors required for glucose-regulated expression, Beta-2/NeuroD1 and Pdx-1, interact with the histone acetylase p300 (17, 26, 40). This prompted us to investigate whether changes in histone acetylation levels play a role in regulation of insulin gene expression by glucose. We report that high concentrations of glucose stimulate insulin gene transcription by mediating hyperacetylation of histone H4 at the insulin gene promoter in the insulinoma cell line MIN6.


    EXPERIMENTAL PROCEDURES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Cell Culture—MIN6 cells of passage 20 to 24 were cultured and maintained in Dulbecco's modified Eagle's medium (DMEM) containing 25 mM glucose, 10% (v/v) fetal bovine serum, 1% penicillin/streptomycin, 2 mM glutamine, and 100 µM {beta}-mercaptoethanol (41). All experiments were carried out with MIN6 cells of passage less than 30. NIH-3T3 fibroblasts (ATCC) were maintained in DMEM with 10% fetal bovine serum and 1% penicillin/streptomycin. For glucose regulation experiments, cells were washed three times with 1x phosphate-buffered saline and grown overnight, unless otherwise indicated, in DMEM without fetal bovine serum containing the indicated glucose concentration(s).

RNA Isolation and RT-PCR—poly(A) RNA from total RNA was isolated using the GenElute Direct mRNA Miniprep kit (Sigma) according to the manufacturer's instructions. After treatment with DNaseI (Sigma), the poly(A) RNA was reverse-transcribed using enhanced avian myeloblastosis virus reverse transcriptase (Sigma). The resulting cDNAs were used as template for PCR with oligonucleotides to amplify the insulin and {beta}-actin genes (42). The oligonucleotide primers used are listed in Table I. The primers for the {beta}-actin gene were designed to cross an intron so that contamination with genomic DNA can be detected, which would result in a PCR product of 330 bp versus 243 bp from the cDNA (43). PCR reactions (20-µl volume) contained 20 ng of cDNA, 300 µM dNTPs, 2.5 pmol of appropriate oligonucleotide primers, and 1.5 units of JumpStart AccuTaq LA DNA polymerase (Sigma). PCR amplification conditions were as follows: 5 min at 95 °C followed by 25 cycles of 95 °C for 30 s, 58 °C for 1 min, and 72 °C for 30 s. The PCR products were separated on 8% non-denaturing polyacrylamide gels and stained with ethidium bromide (Sigma). The bands were visualized using a ChemiDoc System BioRad Imager (Bio-Rad) and quantified using Quantity One imaging software (Bio-Rad) as a function of both band size and band intensity (intensity/mm2).


View this table:
[in this window]
[in a new window]
 
TABLE I
List of sequences of oligonucleotide primers used in this study

 

Chromatin Immunoprecipitation (ChIP)—Chromatin isolation was performed as published previously (31, 44). Approximately 3 x 107 MIN6 or NIH-3T3 cells were cross-linked with formaldehyde (1% final concentration). After lysis of the cells, the nuclear extracts were sonicated with glass beads (0.1 g) for five 10-s pulses at 60% power using a Tekmar Sonic Disruptor. One-third of the sample was used for immunoprecipitation with acetyl-histone H3 (K9, K14) or acetyl-histone H4 (K5, K8, K12, K16) antibodies (Upstate Biotechnology, Inc.). The samples were pre-cleared with 20 µl of blocked Pansorbin Staph A cells (Calbiochem). After 4-fold dilution of the samples in IP buffer (1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.0, 150 mM NaCl) and incubation with 2 µg of specific antibodies or rabbit IgG (Sigma) overnight at 4 °C, the immunocomplexes were recovered by incubation with blocked Staph A cells. After washing twice in dialysis buffer (2 mM EDTA, 50 mM Tris-Cl, pH 8.0, and 0.2% Sarkosyl) and four times with IP wash buffer (1% Nonidet P-40, 100 mM Tris-HCl, pH 8.0, 500 mM LiCl, and 1% deoxycholic acid), the immunocomplexes were eluted twice from the Staph A cells (with 150 µl of 1% SDS in 50 mM NaHCO3). The cross-links were reversed by adding 20 µl of 5 M NaCl and 1 µl of 10 mg/ml RNase A and by incubating at 65 °C for 8 h. After treating with 1.5 µl of proteinase K (10 µg/µl) the samples were extracted with phenol/chloroform and subsequently ethanol-precipitated using 20 µg of glycogen as a carrier.

PCR Analysis of Immunoprecipitated DNA—All PCR reactions were performed on a Robocycler Gradient 96 (Stratagene) in a 20-µl reaction volume containing 50 mM KCl, 10 mM Tris-HCl, pH 8.3, 1.5 mM MgCl, 200 µM dNTPs, and 2 µl of primers (2.5 pmol/µl). The linear range for each primer pair was determined empirically, using different amounts of MIN6 and NIH-3T3 genomic DNA. The PCR reactions and the quantification of the obtained bands were carried out as described above. The PCR products obtained with the immunoprecipitated DNA were normalized to the products obtained with the total input DNA. The primers used for PCR are listed in Table I. A detailed PCR protocol is available upon request. All of the PCR products obtained had the expected size. The identity of the PCR products was confirmed by sequencing.

Statistical Analysis—Comparison of the histone acetylation or insulin mRNA levels from MIN6 cells grown on 3 or 30 mM glucose were performed using the two-tailed, unpaired Student's t test. A p value less than 0.05 was considered statistically significant. Data are expressed as means ± S.D.


    RESULTS
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Glucose Mediates Hyperacetylation of Histone H4 at the Insulin Gene Promoter—To test whether high concentrations of glucose mediate changes in histone acetylation at the insulin gene promoter in the insulinoma cell line MIN6, we utilized the ChIP assay with acetyl histone H3 or acetyl histone H4 antibodies. To quantify the amount of insulin gene promoter associated with acetylated histone H3 or histone H4, the total input and the immunoprecipitated DNA were used as template for PCR with primers against the mouse insulin I gene promoter (covers the promoter region from –10 to –281). The results shown in Fig. 1A indicate that exposure of MIN6 cells to high concentrations of glucose (30 mM) causes an increase in histone H4 acetylation at the insulin gene promoter. However, there is no significant change in acetyl histone H3 levels in response to high levels of glucose.



View larger version (36K):
[in this window]
[in a new window]
 
FIG. 1.
High concentrations of glucose lead to hyperacetylation of histone H4 at the insulin gene promoter that correlates with insulin gene expression. MIN-6 cells were grown on media containing either 3 or 30 mM glucose for 12–18 h and subjected to ChIP assay analysis using anti-acetyl histone H3 or histone H4 antibodies for immunoprecipitation. A, PCR products from immunoprecipitated and total DNA as template using primers against the insulin gene promoter were separated on 8% non-denaturing PAGE gels and stained with ethidium bromide. The antibodies used for immunoprecipitation are indicated to the left of each panel. Rabbit IgG was used as a negative (nonspecific) control for immunoprecipitation. Input DNA was used as template to determine whether equal amounts of total DNA were used in each immunoprecipitation experiment. The quantification of the data from five independent experiments is shown as means ± S.D. in panel B.*, p < 0.001 versus the histone H4 acetylation levels in MIN6 cells grown on 3 mM glucose, n = 5. The quantification of the intensity of the bands was carried out using Bio-Rad Quantity One software. The obtained intensity values are expressed as intensity/mm2. All samples are normalized to the corresponding input DNA. C, RT-PCR analysis of insulin and {beta}-actin mRNA levels in MIN6 cells grown on media containing 3 or 30 mM glucose. The PCR products were analyzed and quantified as described above. The quantification of two independent experiments is displayed in panel D as means ± S.D. *, p < 0.01 versus 3 mM incubated MIN6 cells, n = 2. Primers against the {beta}-actin gene were designed to cross an intron to detect any contaminating genomic DNA. The expected sizes of the two possible products for {beta}-actin are indicated with arrows. The specificity of the acetyl histone H3 or histone H4 antibodies were tested by Western blotting of cell extracts from MIN6 cells incubated with 30 mM glucose (panel E).

 

MIN6 cells incubated with 30 mM glucose displayed an ~4- to 5-fold increase in acetylated histone H4 levels compared with cells incubated with 3 mM glucose in five independent experiments (Fig. 1B). Although in this experiment the MIN6 cells were incubated overnight with low and high glucose media, we observed the increase in histone H4 acetylation even after a 2-h incubation period with 30 mM glucose (data not shown). To verify that the observed increase in histone H4 acetylation levels in response to high glucose concentrations correlated with increases in insulin gene transcription, we quantified the insulin mRNA levels in MIN6 cells grown on low or high glucose media. RT-PCR analysis performed using cDNA from low or high glucose-incubated MIN6 cells indicate a 2.5-fold increase in insulin mRNA levels in response to high glucose (30 mM) compared with the {beta}-actin levels used as control (Fig. 1, C and D). As a control for contamination of the cDNA with genomic DNA, we employed actin primers that give an additional larger PCR product when the sample is contaminated with genomic DNA (Fig. 1, C and D). The acetyl histone H3 and histone H4 antibodies used in this study specifically recognize acetylated histones in Western blots with MIN6 cell extracts (Fig. 1E).

Hyperacetylation of Histone H4 at the GLUT-2 Promoter in Response to Glucose—To test whether glucose causes increases in histone acetylation at other {beta} cell-specific promoters, we used the same immunoprecipitated and total DNA samples as template in PCR analysis with primers against the GLUT-2 promoter (Fig. 2). In the presence of low concentrations of glucose (3 mM), the level of acetylated histone H4 associated with the GLUT-2 promoter was minimal; however, at high concentrations of glucose (30 mM) the acetylated histone H4 levels at the GLUT-2 promoter increased drastically (Fig. 2). The level of acetylated histone H3 at the GLUT-2 promoter remained the same on low and high glucose (Fig. 2). This indicates that high levels of glucose (30 mM) cause hyperacetylation of histone H4 at both insulin and GLUT-2 gene promoters in MIN6 cells.



View larger version (24K):
[in this window]
[in a new window]
 
FIG. 2.
Histone H4 acetylation levels increases at the GLUT-2 promoter in response to 30 mM glucose. MIN-6 cells grown on media containing 3 or 30 mM glucose for 12–18 h were used for ChIP assay analysis with acetylated histone H3 or histone H4 antibodies. A, PCR products obtained from immunoprecipitated and total DNA as template with primers that amplify the GLUT-2 promoter. The PCR products were quantified as described before and are expressed as intensity/mm2. Panel B shows the quantification of two independent experiments as the means ± S.D. *, p < 0.01 versus 3 mM incubated MIN6 cells, n = 2.

 

Histone H4 Acetylation at the Insulin Gene Promoter Is Not Increased at High Concentrations of L-Glucose—Activation of insulin gene transcription is regulated by cellular stress, as well as glucose (48). To test that the observed increase in histone H4 acetylation is not because of secondary effects such osmotic stress caused by the high concentrations of glucose (30 mM) used in this experiment, we repeated the ChIP assay with acetyl histone H3 or histone H4 antibodies using L-glucose. Because L-glucose is not taken up by glucose transporters and thus is not metabolized, it should mimic the osmotic stress caused by high concentrations of extracellular D-glucose.

The analysis of acetylated histone H3 and histone H4 levels associated with the insulin gene promoter in MIN6 cells grown on low (3 mM) or high (30 mM) L-glucose in the presence of 3 mM D-glucose indicates that there is no increase in histone H4 acetylation levels in response to high concentrations of L-glucose (Fig. 3). In summary, these data indicate that glucose causes hyperacetylation of histone H4 at the insulin gene promoter and that this effect is specific and is not caused by osmotic stress.



View larger version (25K):
[in this window]
[in a new window]
 
FIG. 3.
Glucose-stimulated hyperacetylation of histone H4 is not due to osmotic effects. MIN6 cells were pre-grown in DMEM without serum and 3 mM glucose overnight and then transferred to media containing 3 mM D-glucose in combination with either 3 or 30 mM L-glucose for 2 h. ChIP assays were performed with anti-acetyl histone H3 or histone H4 antibodies as indicated (panel A) and quantified as described before. The quantification of histone H4 acetylation levels at the insulin gene promoter from two independent experiments is shown in panel B as means ± S.D., n = 2 and is compared with the histone H4 acetylation levels in MIN6 cells incubated with 3 or 30 mM D-glucose.

 

Histone H4 Hyperacetylation at the Insulin and GLUT-2 Gene Promoters Increases in a Glucose Concentration-dependent Manner—It has been shown previously (1, 49) that insulin mRNA levels increase in a dose-dependent fashion in response to increasing glucose concentrations. To analyze the effects of increasing concentrations of glucose on the level of histone H4 acetylation at the insulin gene promoter, MIN6 cells were incubated in media containing 3, 5, 10, or 20 mM glucose for 3 h. Analysis of histone H3 and histone H4 acetylation levels using the ChIP assay demonstrated that histone H3 acetylation did not change significantly at the insulin and GLUT-2 gene promoters by increasing the glucose concentration (Fig. 4). However, the acetylation level of histone H4 at both promoters increased in parallel with increasing the glucose concentration (Fig. 4). As a control for this experiment we amplified the cad (carbamoyl phosphate synthase/aspartate transcarbamoylase/dihydroorotase) gene promoter using the same DNA immunoprecipitated with acetyl histone H3 or histone H4 antibodies and total DNA as template. We found that the levels of histone H3 acetylation at the cad promoter, whose expression is not glucose-regulated, did not change in response to increases in glucose concentration (Fig. 4, third panel). This experiment again confirms that the observed hyperacetylation of histone H4 at the insulin and GLUT-2 promoters is glucose-specific.



View larger version (35K):
[in this window]
[in a new window]
 
FIG. 4.
Histone H4 acetylation increases in a glucose concentration-dependent manner. MIN6 cells were grown for3hin DMEM without glucose prior to incubation for 3 h with different concentrations of glucose as indicated. The ChIP assay was carried out using anti-acetyl histone H3 or histone H4 antibodies as described before. The PCR products obtained by using primers to amplify the insulin, GLUT-2, and cad gene promoters are shown. The data shown are representative of two independent experiments.

 

The Decrease in Histone H4 Acetylation on Low Glucose Is Mediated by the Recruitment of Histone Deacetylases to the Insulin Gene Promoter—Histone deacetylases such as HDAC1 and HDAC2 have been shown to repress gene expression by decreasing the acetylation status of histones at specific promoters (28). Therefore, it was possible that the decrease in histone H4 acetylation on low levels of glucose (3 mM) was because of the recruitment of histone deacetylases to the insulin gene promoter. To address this question, we carried out the ChIP assay using acetyl histone H3 or histone H4 antibodies in MIN6 cells grown on media containing low or high glucose, in the presence or absence of the histone deacetylase inhibitors trichostatin A (TSA) or sodium butyrate. The inhibition of histone deacetylases in MIN6 cells resulted in equal levels of both histone H3 and H4 acetylation at the insulin gene promoter on low and high concentrations of glucose (Fig. 5A). We obtained similar results with both inhibitors; however, the acetylation levels of both histone H3 and histone H4 were consistently lower with sodium butyrate-treated samples in three independent experiments, which is likely due to additional effects that sodium butyrate has on cultured cells (50). The level of histone H4 acetylation at the insulin gene promoter on low levels of glucose was very similar to that of high concentrations of glucose. These data suggest that the reduced level of histone H4 acetylation on low concentrations of glucose is likely because of the active recruitment of deacetylases to the insulin gene promoter.



View larger version (23K):
[in this window]
[in a new window]
 
FIG. 5.
The decrease in histone H4 acetylation levels on low glucose is due to the recruitment of histone deacetylases to the insulin gene promoter. MIN6 cells were grown on media containing 3 or 30 mM glucose for 12–18 h with or without TSA or sodium butyrate (NaB) as indicated. ChIP assays were performed using anti-acetyl histone H3 or histone H4 antibodies. The PCR products obtained using primers to amplify the insulin gene promoter are shown in panel A. The quantification of the intensity of the obtained PCR products from three independent experiments is shown in panel B for the TSA and in panel C for the sodium butyrate treatment as means ± S.D., n = 3.

 

To test whether the increase in histone H4 acetylation on low concentrations of glucose as observed with TSA treatment causes increased insulin gene transcription, we quantified the expression level of the insulin gene in MIN6 cells grown on media containing low or high concentrations of glucose treated with TSA by RT-PCR analysis. As shown in Fig. 6, the levels of insulin mRNA in MIN6 cells grown on low glucose-containing media was equal to that of high glucose-grown cells following TSA treatment. The obtained data are consistent with the idea that the decrease in histone H4 acetylation levels at the insulin gene promoter on low levels of glucose is because of the action of deacetylases and that increases in histone H4 acetylation levels correlate with increased insulin gene expression.



View larger version (21K):
[in this window]
[in a new window]
 
FIG. 6.
Inhibition of histone deacetylases in MIN6 cells causes constitutive expression of the insulin gene. MIN6 cells grown on low glucose (3 mM)- or high glucose (30 mM)-containing media were treated with or without 100 ng/ml TSA for 15 h. After isolation of total RNA, RT-PCR analysis was performed to determine the mRNA levels of insulin and {beta}-actin as control. The obtained PCR products were resolved on a PAGE gel (panel A), and the intensity of the bands was quantified (panel B). The data from two independent experiments are expressed as means ± S.D., n = 2.

 

Lack of Insulin Gene Expression in Fibroblasts Is Associated with a Lack of Histone Acetylation at the Insulin Gene Promoter—It has been shown that acetylated histones are normally associated with promoters of actively transcribed genes (28, 29). Silent genes appear to either lack or have only minimal levels of histone acetylation at their promoter regions. To confirm our finding that increases in histone acetylation correlate with increased insulin gene transcription, we have analyzed the levels of acetylated histones associated with the insulin gene promoter in the mouse fibroblast cell line NIH-3T3, where the insulin gene is normally not expressed. For this experiment, NIH-3T3 fibroblasts grown on low or high concentrations of glucose were subjected to ChIP assay analysis using the anti-acetyl histone H3 and histone H4 antibodies. As expected, there was no detectable acetylation of either histone H3 or histone H4 at the silent insulin gene promoter in the NIH-3T3 fibroblast cell line (Fig. 7). PCR analysis of the cad promoter, using the same immunoprecipitated DNA as template, demonstrated detectable levels of histone H3 acetylation at this active promoter in NIH-3T3 cells as was seen in the MIN6 cell line.



View larger version (30K):
[in this window]
[in a new window]
 
FIG. 7.
NIH-3T3 fibroblasts lack histone acetylation at the insulin gene promoter. NIH-3T3 cells were grown on media containing 3 or 30 mM glucose for 12–18 h before being used in ChIP assays with acetyl histone H3 or H4 antibodies. PCR products obtained from immunoprecipitated and total DNA as template using primers to amplify the insulin (upper panel) and the cad gene promoters (lower panel) are shown. The results are representative of three independent experiments.

 


    DISCUSSION
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 
Recent data indicate that the homeodomain transcription factor Pdx-1 and Beta-2/NeuroD1, required for glucose-stimulated expression of the insulin gene, interact with the histone acetylase p300 (17, 26, 40). This suggested that changes in histone acetylation might be important in the regulation of the insulin gene transcription. We report that exposure of MIN6 cells to high concentrations of glucose stimulates insulin gene expression and results in hyperacetylation of histone H4 at the insulin gene promoter.

High concentrations of L-glucose, which is not taken up by the cells, has no effect on histone acetylation excluding the possibility that hyperacetylation of histone H4 at 30 mM glucose is mediated by osmotic stress. The fact that histone H4 acetylation occurs in a glucose concentration-dependent manner also indicates that hyperacetylation of histone H4 at the insulin gene promoter in response to glucose is specific. Because the level of histone H3 acetylation is not changed in response to glucose at the insulin gene promoter, this may be responsible for maintaining basal transcription whereas hyperacetylation of histone H4 would function to up-regulate insulin gene transcription only in response to high blood glucose levels. Several transcription factors activate gene expression by mediating hyperacetylation of histone H4, including the transcription factor c-myc (51).

High concentrations of glucose also lead to hyperacetylation of histone H4 at the GLUT-2 gene promoter, indicating that glucose regulation of {beta} cell-specific gene expression may be in general mediated by increases in histone H4 acetylation. Recent data indicate that HNF1{alpha} is required for expression of the GLUT-2 gene but not of the insulin I and II genes (52, 53). HNF1{alpha} has been shown to regulate GLUT-2 expression by direct binding to its promoter and by causing hyperacetylation at the GLUT-2 promoter via recruitment of histone acetylases (52, 54). Both acetylated histone H3 and histone H4 levels decrease in the HNF1{alpha} homozygous knockout mice (52). Interestingly, HNF1{alpha} is also required for expression of the transcription factors Pdx-1 and Beta-2/NeuroD1 (53). We have observed only changes in histone H4 acetylation levels at the GLUT-2 promoter whereas histone H3 acetylation did not significantly change in response to high concentrations of glucose. The region of the GLUT-2 promoter analyzed in this study covers the sequences from –523 to –738 with respect to the transcription initiation site, which is more upstream than the region used in the studies with HNF1{alpha} (52). This specific promoter region was chosen, because it has been shown previously (55) to be sufficient for glucose regulation of GLUT-2 gene expression and contains binding sites for the transcription factor Pdx-1.

This is the first example of nutrient regulation of gene expression by mediating changes in histone acetylation. However, the expression of several genes have been shown to be regulated through modulation of histone acetylation in response to external stimuli. For example, the stimulus for upregulation of interferon-{beta} expression is viral infection, which requires various factors including NF-{kappa}B, CBP, Gcn5, TBP, TAFII250, and RNA polymerase II (56). The recruitment of these factors, as well as increased transcription, correlates with increases in the acetylation levels of histones H3 and histone H4 at this promoter (57). Acetylated histones are associated with promoters of actively transcribed genes whereas silent genes appear to either lack or have only minimal histone acetylation at their promoter regions (28). Consistent with this idea, the fibroblast NIH-3T3 cell line where the insulin gene is silent lacks histone acetylation at the insulin gene promoter.

Tissue-specific expression of genes is mediated by the action of specific transcription factors that can modulate the histone structure at specific promoters by interacting with co-activators or co-repressors. For instance, the muscle-specific transcription factor MyoD has been shown to be essential for myoblast differentiation through activation of a number of muscle-specific genes (58). In undifferentiated myoblasts, MyoD has been shown to interact with class I histone deacetylases HDAC1 and HDAC2; however, it interacts with the histone acetylases PCAF and p300 to drive transcription in myotubes (59, 60). Because the region of the insulin gene promoter amplified by PCR in our studies contains binding sites for Pdx-1, Beta-2, and Ribe3b1, it is likely that one or several of these transcription factors are responsible for mediating the hyperacetylation of histone H4 in response to high concentrations of glucose. Indeed Pdx-1 and Beta-2/NeuroD1 have been shown to interact with the histone acetylase p300 (17, 26, 40). Furthermore, it has been demonstrated that introduction of a recombinant Pdx-1 adenovirus into livers of mice leads to the expression of endogenous, otherwise silent, genes for mouse insulin I and II, suggesting that Pdx-1 itself is sufficient to activate insulin gene expression in the liver (61). These data suggest the idea that high concentrations of glucose cause hyperacetylation of histone H4 at the insulin gene promoter by the recruitment of the histone acetylase p300 via Pdx-1 and/or Beta-2 that leads to up-regulation of insulin gene transcription.

This idea is also supported by the fact that another chromatin-associated protein, HMGI(Y), has been shown to bind to the A3/A4 region of the insulin promoter and to enhance the in vitro DNA binding of a complex containing Pdx-1 and E47/Pan-1 transcription factors (25). The HMGI(Y) family of proteins has been implicated in the formation of enhanceosome, which are complexes that allow synergistic regulation of promoter regions by a number of transcriptional factors (62).

Treatment of MIN6 cells with histone deacetylase inhibitors results in increased histone H4 acetylation at the insulin gene promoter independent of glucose concentration, which leads to increased insulin gene transcription, even in the absence of high concentrations of glucose. These data indicate that the decreased levels of histone H4 acetylation observed on low glucose are because of the active recruitment of histone deacetylases to the insulin gene promoter. Class I histone deacetylases, specifically HDAC1 and HDAC2, have been implicated in repression of gene expression (63). It is possible that on low concentrations of glucose, expression of the insulin gene is kept low by the recruitment of deacetylases such as HDAC1 and HDAC2. At high concentrations of glucose the recruitment of a histone acetylase, such as p300, could cause up-regulation of insulin gene expression by hyperacetylation of histone H4. It has been demonstrated that the interplay between histone acetyltransferases and histone deacetylases is the key to the dynamics of chromatin structure and function. Indeed, NF-{kappa}B has been shown to interact with both p300 and HDAC1 in a phosphorylation-dependent manner (64). Another transcription factor, HIF-1, is also negatively regulated by HDAC1 (65). However, it associates with p300/CBP to function as a transcriptional activator. The association of HIF-1 with HDAC1 or p300 is regulated by the O2 concentration (66). Experiments are under way to test the recruitment of HDACs and p300 to the insulin gene promoter in a glucose-dependent manner.

Our data indicate that up-regulation of insulin gene expression in response to high blood glucose levels is mediated by hyperacetylation of histone H4. Because this up-regulation of insulin gene expression at high glucose concentrations is essential in maintaining glucose homeostasis, dysregulation of histone acetylation levels at the insulin gene promoter may be an important cause of insulin insufficiency leading to diabetes. Understanding the role of histone modification in glucose-stimulated insulin gene expression may be valuable for the engineering of non-{beta} cells such as the liver to produce and secrete insulin in a glucose-dependent manner.


    FOOTNOTES
 
* This work was supported in part by a grant from the Juvenile Diabetes Research Foundation International (to S. Ö.) and by a predoctoral fellowship from the American Heart Association (to A. L. M.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. Back

{ddagger} To whom correspondence should be addressed: Dept. of Molecular and Cellular Biochemistry, University of Kentucky, College of Medicine, 800 Rose St., MN 608, Lexington, KY 40536. Tel.: 859-257-4821; Fax: 859-323-1037; E-mail: sozcan{at}uky.edu.

1 The abbreviations used are: GLUT-2, glucose transporter-2; Ac, acetyl; TSA, trichostatin A; MIN6, mouse insulinoma 6; IP, immunoprecipitation; ChIP, chromatin IP; DMEM, Dulbecco's modified Eagle's medium; RT, reverse transcriptase; NHF1{alpha}, hepatocyte nuclear factor-1alpha. Back


    ACKNOWLEDGMENTS
 
We thank Dr. C. Waechter and Dr. S. Turco and the members of their laboratories for providing access to their Thermocycler and Imager, respectively. We also thank the members of the Department of of Molecular and Cellular Biochemistry, University of Kentucky for valuable discussions and advice and Taquoya Owens for technical assistance. In addition, we thank Drs. J. Miyazaki, R. Stein, D. Steiner, and J. Hutton for providing the MIN6 cell line.



    REFERENCES
 TOP
 ABSTRACT
 INTRODUCTION
 EXPERIMENTAL PROCEDURES
 RESULTS
 DISCUSSION
 REFERENCES
 

  1. LeRoith, D., Taylor, S. I., and Olefsky, J. M. (2000) Diabetes Mellitus: A Fundamental and Clinical Text, 2nd Ed., Lippincott Williams and Wilkins, Philadelphia, Baltimore, New York, London, Buenos Aires, Hong Kong, Sydney, Tokyo
  2. Newgard, C. B., and McGarry, J. D. (1995) Ann. Rev. Biochem. 64, 689–719[CrossRef][Medline] [Order article via Infotrieve]
  3. Unger, R. H. (1991) Science 251, 1200–1205[Medline] [Order article via Infotrieve]
  4. Waeber, G., Thompson, N., Haefliger, J. A., and Nicod, P. (1994) J. Biol. Chem. 269, 26912–26919[Abstract/Free Full Text]
  5. Bonny, C., Roduit, R., Gremlich, S., Nicod, P., Thorens, B., and Waeber, G. (1997) Mol. Cell. Endocrinol. 135, 59–65[CrossRef][Medline] [Order article via Infotrieve]
  6. Brissova, M., Shiota, M., Nicholson, W. E., Gannon, M., Knobel, S. M., Piston, D. W., Wright, C. V., and Powers, A. C. (2002) J. Biol. Chem. 277, 11225–11232[Abstract/Free Full Text]
  7. Leibiger, B., Leibiger, I. B., Moede, T., Kemper, S., Kulkarni, R. N., Kahn, C. R., de Vargas, L. M., and Berggren, P. O. (2001) Mol. Cell 7, 559–570[Medline] [Order article via Infotrieve]
  8. da Silva Xavier, G., Varadi, A., Ainscow, E. K., and Rutter, G. A. (2000) J. Biol. Chem. 275, 36269–36277[Abstract/Free Full Text]
  9. Shih, D. Q., Heimesaat, M., Kuwajima, S., Stein, R., Wright, C. V., and Stoffel, M. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 3818–3823[Abstract/Free Full Text]
  10. Melloul, D., Marshak, S., and Cerasi, E. (2002) Diabetologia 45, 309–326[CrossRef][Medline] [Order article via Infotrieve]
  11. German, M. S., and Wang, J. (1994) Mol. Cell. Biol. 14, 4067–4075[Abstract]
  12. Petersen, H. V., Serup, P., Leonard, J., Michelsen, B. K., and Madsen, O. D. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 10465–10469[Abstract/Free Full Text]
  13. Melloul, D., Ben-Neriah, Y., and Cerasi, E. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 3865–3869[Abstract]
  14. Sharma, A., and Stein, R. (1994) Mol. Cell. Biol. 14, 871–879[Abstract]
  15. Sharma, A., Fusco-DeMane, D., Henderson, E., Efrat, S., and Stein, R. (1995) Mol. Endocrinol. 9, 1468–1476[Abstract]
  16. Sander, M., Griffen, S. C., Huang, J., and German, M. S. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 11572–11577[Abstract/Free Full Text]
  17. Sharma, A., Moore, M., Marcora, E., Lee, J. E., Qiu, Y., Samaras, S., and Stein, R. (1999) Mol. Cell. Biol. 19, 704–713[Abstract/Free Full Text]
  18. Ohlsson, H., Karlsson, K., and Edlund, T. (1993) EMBO J. 12, 4251–4259[Abstract]
  19. Miller, C. P., McGehee, R. E., and Habener, J. F. (1994) EMBO J. 13, 1145–1156[Abstract]
  20. Serup, P., Petersen, H. V., Pedersen, E. E., Edlund, H., Leonard, J., Petersen, J. S., Larsson, L. I., and Madsen, O. D. (1995) Biochem. J. 310, 997–1003[Medline] [Order article via Infotrieve]
  21. Zhao, L., Cissell, M. A., Henderson, E., Colbran, R., and Stein, R. (2000) J. Biol. Chem. 275, 10532–10537[Abstract/Free Full Text]
  22. Olbrot, M., Rud, J., Moss, L. G., and Sharma, A. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 6737–6742[Abstract/Free Full Text]
  23. Kataoka, K., Han, S. I., Shioda, S., Hirai, M., Nishizawa, M., and Handa, H. (2002) J. Biol. Chem. 51, 49903–49910[CrossRef]
  24. Dutta, S., Gannon, M., Peers, B., Wright, C., Bonner-Weir, S., and Montminy, M. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 1065–1070[Abstract/Free Full Text]
  25. Ohneda, K., Mirmira, R. G., Wang, J., Johnson, J. D., and German, M. S. (2000) Mol. Cell. Biol. 20, 900–911[Abstract/Free Full Text]
  26. Qiu, Y., Guo, M., Huang, S., and Stein, R. (2002) Mol. Cell. Biol. 22, 412–420[Abstract/Free Full Text]
  27. Shinozuka, Y., Okada, M., Oki, T., Sagane, K., Mizui, Y., Tanaka, I., Katayama, K., and Murakami-Murofushi, K. (2001) Biochem. Biophys. Res. Commun. 287, 229–235[CrossRef][Medline] [Order article via Infotrieve]
  28. Berger, S. L. (2002) Curr. Opin. Genet. Dev. 12, 142–148[CrossRef][Medline] [Order article via Infotrieve]
  29. Cheung, P., Allis, C. D., and Sassone-Corsi, P. (2000) Cell 103, 263–271[Medline] [Order article via Infotrieve]
  30. Struhl, K. (2001) Science 293, 1054–1055[Free Full Text]
  31. Eberhardy, S. R., D'Cunha, C. A., and Farnham, P. J. (2000) J. Biol. Chem. 275, 33798–33805[Abstract/Free Full Text]
  32. Lomvardas, S., and Thanos, D. (2002) Cell 110, 261–271[Medline] [Order article via Infotrieve]
  33. Cheung, W. L., Briggs, S. D., and Allis, C. D. (2000) Curr. Opin. Cell Biol. 12, 326–333[CrossRef][Medline] [Order article via Infotrieve]
  34. Sterner, D. E., and Berger, S. L. (2000) Microbiol. Mol. Biol. Rev. 64, 435–459[Abstract/Free Full Text]
  35. Brownell, J. E., and Allis, C. D. (1996) Curr. Opin. Genet. Dev. 6, 176–184[CrossRef][Medline] [Order article via Infotrieve]
  36. Roth, S. Y., Denu, J. M., and Allis, C. D. (2001) Annu. Rev. Biochem. 70, 81–120[CrossRef][Medline] [Order article via Infotrieve]
  37. Mahadevan, L. C., Willis, A. C., and Barrat, M. J. (1991) Cell 65, 775–783[Medline] [Order article via Infotrieve]
  38. Rea, S., Eisenhuber, F., O'Carroll, D., Strahl, B. D., Sun, Z. W., Schmid, M., Opravil, S., Mechtler, K., Ponting, C. P., Allis, C. D., and Jenuwein, T. (2000) Nature 406, 593–599[CrossRef][Medline] [Order article via Infotrieve]
  39. Turner, B. M. (1993) Cell 75, 5–8[Medline] [Order article via Infotrieve]
  40. Qiu, Y., Sharma, A., and Stein, R. (1998) Mol. Cell. Biol. 18, 2957–2964[Abstract/Free Full Text]
  41. Miyazaki, J., Araki, K., Yamato, E., Ikegami, H., Asano, T., Shibasaki, Y., Oka, Y., and Yamamura, K. (1990) Endocrinology 127, 126–132[Abstract]
  42. Roderigo-Milne, H., Hauge-Evans, A. C., Persaud, S. J., and Jones, P. M. (2002) Biochem. Biophys. Res. Commun. 296, 589–595[CrossRef][Medline] [Order article via Infotrieve]
  43. Rout, U. K., and Armant, D. R. (2002) Reprod. Toxicol. 16, 253–258[CrossRef][Medline] [Order article via Infotrieve]
  44. Wells, J., and Farnham, P. J. (2002) Methods 26, 48–56[CrossRef][Medline] [Order article via Infotrieve]
  45. Steiner, D. F., Chan, S. J., Welsh, J. M., and Kwok, S. C. (1985) Annu. Rev. Genet. 19, 463–484[CrossRef][Medline] [Order article via Infotrieve]
  46. Boyd, K. E., Wells, J., Gutman, J., Bartley, S. M., and Farnham, P. J. (1998) Proc. Natl. Acad. Sci. U. S. A. 95, 13887–13892[Abstract/Free Full Text]
  47. Chakrabarti, S. K., James, J. C., and Mirmira, R. G. (2002) J. Biol. Chem. 277, 13286–13293[Abstract/Free Full Text]
  48. Macfarlane, W. M., McKinnon, C. M., Felton-Edkins, Z. A., Cragg, H., James, R. F., and Docherty, K. (1999) J. Biol. Chem. 274, 1011–1016[Abstract/Free Full Text]
  49. Macfarlane, W. M., Shepherd, R. M., Cosgrove, K. E., James, R. F., Dunne, M. J., and Docherty, K. (2000) Diabetes 49, 418–423[Abstract]
  50. Candido, E. P., Reeves, R., and Davie, J. R. (1978) Cell 14, 105–113[Medline] [Order article via Infotrieve]
  51. Frank, S. R., Schroeder, M., Fernandez, P., Taubert, S., and Amati, B. (2001) Genes Dev. 15, 2069–2082[Abstract/Free Full Text]
  52. Parrizas, M., Maestro, M. A., Boj, S. F., Paniagua, A., Casamitjana, R., Gomis, R., Rivera, F., and Ferrer, J. (2001) Mol. Cell. Biol. 21, 3234–3243[Abstract/Free Full Text]
  53. Shih, D. Q., Screenan, S., Munoz, K. N., Philipson, L., Pontoglio, M., Yaniv, M., Polonsky, K. S., and Stoffel, M. (2001) Diabetes 50, 2472–2480[Abstract/Free Full Text]
  54. Soutoglou, E., Papafotiou, G., Katrakili, N., and Talianidis, I. (2000) J. Biol. Chem. 275, 12515–12520[Abstract/Free Full Text]
  55. Waeber, G., Thompson, N., Nicod, P., and Bonny, C. (1996) Mol. Endocrinol. 10, 1327–1334[Abstract]
  56. Agalioti, T., Lomvardas, S., Parekh, B., Yie, J., Maniatis, T., and Thanos, D. (2000) Cell 103, 667–678[Medline] [Order article via Infotrieve]
  57. Parekh B. S., and Maniatis, T. (1999) Mol. Cell. 3, 125–129[Medline] [Order article via Infotrieve]
  58. Gu, W., Schneider, J. W., Condorelli, G., Kaushal, S., Mahdavi, V., and Nadal-Ginard, B. (1993) Cell 72, 309–324[Medline] [Order article via Infotrieve]
  59. Puri, P., Iezzi, S., Stiegler, P., Chen, T., Schilz, R. L., Muscat, G., Giordano, A., Kedes L., Wang, J., and Sartorelli, V. (2001) Mol. Cell 8, 885–897[Medline] [Order article via Infotrieve]
  60. Puri, P., Avantaggiati, M. L., Balsano, C., Sang, N., Graessmann, A., Giordano, A., and Levrero, M. (1997) EMBO J. 16, 369–383[Abstract/Free Full Text]
  61. Ferber, S., Halkin, A., Cohen, H., Ber, I., Einav, Y., Goldberg, I., Barshack, I., Seijffers, R., Kopolovic, J., Kaiser, N., and Karasik, A. (2000) Nat. Med. 6, 568–572[CrossRef][Medline] [Order article via Infotrieve]
  62. Munshi, N., Agalioti, T., Lomvardas, S., Merika, M., Chen, G., and Thanos, D. (2001) Science 293, 1133–1136[Abstract/Free Full Text]
  63. Heinzel, T., Lavinsky, R. M., Mullen, T. M., Soderstrom, M., Laherty, C. D., Torchia, J., Yang, W. M., Brard, G., Ngo, S. D., Davie, J. R., Seto, E., Eisenman, R. N., Rose, D. W., Glass, C. K., and Rosenfeld, M. G. (1997) Nature 387, 43–48[CrossRef][Medline] [Order article via Infotrieve]
  64. Zhong, H., May, M. J., Jimi, E., and Ghosh, S. (2002) Mol. Cell. 9, 625–636[Medline] [Order article via Infotrieve]
  65. Mahon, P. C., Hirota, K., and Semenza, G. L. (2001) Genes Dev. 15, 2675–2686[Abstract/Free Full Text]
  66. Semenza, G. L. (2002) Proc. Natl. Acad. Sci. U. S. A. 99, 11570–11572[Free Full Text]